Therapy News and Research

RSS

Scientists uncover why some people more prone to major depression

Scientists are beginning to unwrap the biology behind why some people are more prone to major depression and other psychiatric disorders than others when experiencing stressful life events. The researchers found that cellular activity in response to stress hormone receptor activation differs from individual to individual.

4 Jun 2015

New study suggests that IDH1 gene may be prognostic marker for anaplastic astrocytoma

New findings suggest that a gene called IDH1 might be prognostic marker for a rare form of brain cancer. Patients in this study who had a mutated IDH gene lived an average of 7.9 years after diagnosis versus 2.8 years for patients with unaltered IDH.

4 Jun 2015

Varian selected to equip, service HollandPTC in Delft with ProBeam proton therapy system

Varian Medical Systems today announced that it has been selected to equip and service the new multi-room HollandPTC in Delft with the Varian ProBeam proton therapy system. The company will book the equipment part of the order in its fiscal 2015 third quarter.

3 Jun 2015

BioLife reports increased use of CryoStor and HypoThermosol biopreservation media products in clinical studies

BioLife Solutions, Inc., a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers, today reported several new customer disclosures on the use of the Company's CryoStor and HypoThermosol biopreservation media products in pre-clinical validation projects and clinical trials at the recent International Society for Cellular Therapy (ISCT) conference.

3 Jun 2015

Takara Bio Europe launches Cellartis DEF-CS Xeno-Free Culture Medium for iPS cell culture

Takara Bio Europe AB, formerly Cellartis AB, a wholly-owned subsidiary of Takara Bio Inc., announced today that it is launching an advanced cell culture medium for iPS cell culture. This chemically-defined culture medium is pre-clinical grade, free from human- and animal-derived components, and designed for efficient expansion of undifferentiated human iPS cells.

3 Jun 2015

Genentech, Seragon, Regeneron and Avalanche receive Allicense 2015 Breakthrough Award for Deals of the Year

The Intellectual Property and Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, recently honored Genentech Partnering and Seragon, and Regeneron and Avalanche with the Allicense 2015 Breakthrough Award for Deals of the Year.

3 Jun 2015

Ultrasound becoming the most widely used imaging tool in medicine today

Mention "ultrasound" and most people likely will think of an image of a fetus in a mother's womb. But while providing peeks at the not-yet-born is one of ultrasound's most common applications, that's only a small part of the picture.

3 Jun 2015

Community Health Network, University of Indianapolis partner to establish clinical facility on campus

Community Health Network and the University of Indianapolis are joining forces to establish a clinical facility on campus where students and faculty will work alongside health and wellness professionals to serve patients and clients, transforming the educational experience and bringing important resources to an underserved part of the city.

3 Jun 2015

Women who suffer from fibromyalgia benefit from hyperbaric oxygen therapy

Women who suffer from fibromyalgia benefit from a treatment regimen in a hyperbaric oxygen chamber, according to researchers at Rice University and institutes in Israel.

3 Jun 2015

MGH researchers develop bioartificial replacement limbs suitable for transplantation

A team of Massachusetts General Hospital investigators has made the first steps towards development of bioartificial replacement limbs suitable for transplantation. In their report, which has been published online in the journal Biomaterials, the researchers describe using an experimental approach previously used to build bioartificial organs to engineer rat forelimbs with functioning vascular and muscle tissue.

3 Jun 2015

BioCision, CCT to develop ThawSTAR automated cell thawing system for treatment of diabetic foot ulcers

BioCision, LLC, a leader in advanced technology to improve biological sample handling and standardization, today announced that it will collaborate with Celgene Cellular Therapeutics (CCT) (a subsidiary of Celgene Corporation), to accelerate the development of a cell thawing solution based on BioCision’s proprietary ThawSTARÔ technology for the 6 mL injectable vial that CCT has chosen to store PDA-002, a cryopreserved, allogeneic cell therapy currently in clinical development to treat diabetic foot ulcers in patients with peripheral arterial disease.

3 Jun 2015

Ovizio unveils new in-line suspension cell-monitoring microscope at ESACT

Ovizio Imaging System, an innovative quantitative microscopy company specializing in life science solutions, announces today the launch of its new product, the iLine F, an in-line suspension cell-monitoring microscope.

3 Jun 2015

CheckMate for nivolumab in untreated melanoma, squamous NSCLC

Two phase III trials published in The New England Journal of Medicine support the use of nivolumab in patients with treatment-naïve metastatic melanoma and in those with squamous non-small-cell lung cancer who have failed first-line chemotherapy.

2 Jun 2015

Nivolumab and pembrolizumab therapies continue to show promise against advanced melanomas

Results of two clinical trials reported at the American Society for Clinical Oncology Annual Meeting 2015 show continued promise of immune therapies nivolumab and pembrolizumab against advanced melanomas, specifically in the context of PD1 signaling that some tumors use to avoid immune system attack. Dr. Rene Gonzalez, MD, investigator at the University of Colorado Cancer Center and director of the Melanoma Research Clinics at the CU School of Health, is an author of both studies.

2 Jun 2015

New finding may lead to development of immunity-based therapies for tuberculosis

A study by researchers at UT Southwestern Medical Center has identified how an enzyme involved in protecting the body from pathogens senses Mycobacterium tuberculosis (TB), a bacterial pathogen that infects millions of people worldwide and causes about 1.5 million deaths annually.

2 Jun 2015

MorphoSys' MOR202 proprietary drug candidate meets primary endpoints in multiple myeloma patients

MorphoSys AG today published first safety and efficacy data on its proprietary drug candidate MOR202. The data are from a phase 1/2a study in 42 heavily pretreated patients with relapsed/refractory multiple myeloma.

2 Jun 2015

Celldex’s lead program RINTEGA demonstrates overall survival benefit in patients with recurrent glioblastoma

Celldex Therapeutics, Inc. today presented positive results from the Company’s randomized, double‐blind Phase 2 study of RINTEGA (rindopepimut) in patients with EGFRvIII‐positive, recurrent glioblastoma at the 2015 American Society of Clinical Oncology in Chicago.

2 Jun 2015

Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

OncoGenex Pharmaceuticals, Inc. announced that results from an exploratory analysis of the Phase 2 Borealis-1 trial showed that metastatic bladder cancer patients with poor prognostic features benefited from apatorsen 600mg added to first-line chemotherapy compared to chemotherapy alone.

2 Jun 2015

EMA grants Orphan Drug Designation to Stempeucel for treatment of Thromboangiitis Obliterans

Stempeutics Research, a group company of Manipal Education & Medical Group and a joint venture with Cipla Group, announced today that the European Medicines Agency (EMA) has granted Orphan Drug Designation for its drug Stempeucel® for the treatment of Thromboangiitis Obliterans.

2 Jun 2015

MedImmune, AstraZeneca present encouraging results from new combination-focused immuno-oncology portfolio at ASCO 2015

AstraZeneca and MedImmune, the company’s global biologics research and development arm, today presented encouraging results from their novel combination-focused immuno-oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting 2015.

2 Jun 2015

Therapy News and Research

Scientists uncover why some people more prone to major depression

New study suggests that IDH1 gene may be prognostic marker for anaplastic astrocytoma

Varian selected to equip, service HollandPTC in Delft with ProBeam proton therapy system

BioLife reports increased use of CryoStor and HypoThermosol biopreservation media products in clinical studies

Takara Bio Europe launches Cellartis DEF-CS Xeno-Free Culture Medium for iPS cell culture

Genentech, Seragon, Regeneron and Avalanche receive Allicense 2015 Breakthrough Award for Deals of the Year

Ultrasound becoming the most widely used imaging tool in medicine today

Community Health Network, University of Indianapolis partner to establish clinical facility on campus

Women who suffer from fibromyalgia benefit from hyperbaric oxygen therapy

MGH researchers develop bioartificial replacement limbs suitable for transplantation

BioCision, CCT to develop ThawSTAR automated cell thawing system for treatment of diabetic foot ulcers

Ovizio unveils new in-line suspension cell-monitoring microscope at ESACT

CheckMate for nivolumab in untreated melanoma, squamous NSCLC

Nivolumab and pembrolizumab therapies continue to show promise against advanced melanomas

New finding may lead to development of immunity-based therapies for tuberculosis

MorphoSys' MOR202 proprietary drug candidate meets primary endpoints in multiple myeloma patients

Celldex’s lead program RINTEGA demonstrates overall survival benefit in patients with recurrent glioblastoma

Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

EMA grants Orphan Drug Designation to Stempeucel for treatment of Thromboangiitis Obliterans

MedImmune, AstraZeneca present encouraging results from new combination-focused immuno-oncology portfolio at ASCO 2015

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News